(Q34756641)

4 August 2017

0 references

Safety and tolerability of intravenous-to-oral treatment and single-dose intravenous or oral prophylaxis with trovafloxacin (English)

1 reference

4 August 2017

Williams DJ

1

1 reference

4 August 2017

Hopkins S

series ordinal

2

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 December 1998

1 reference

The American Journal of Surgery

4 August 2017

published in

1 reference

4 August 2017

volume

176

1 reference

4 August 2017

issue

6A Suppl

1 reference

4 August 2017

page(s)

74S-79S

1 reference

The chemistry and biological profile of trovafloxacin

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900224-4

In vitro activity of the new fluoroquinolone CP-99,219.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900224-4

Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900224-4

In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900224-4

In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900224-4

Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900224-4

Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900224-4

Oral bioavailability of trovafloxacin with and without food in healthy volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900224-4

A double-blind, placebo-controlled, parallel group study of oral trovafloxacin on bowel microflora in healthy male volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900224-4

Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900224-4

The pharmacokinetic effects of coadministration of morphine and trovafloxacin in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900224-4

Double-blind comparison of single-dose alatrofloxacin and cefotetan as prophylaxis of infection following elective colorectal surgery. Trovafloxacin Surgical Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900224-4

Oral trovafloxacin compared with intravenous cefoxitin in the prevention of bacterial infection after elective vaginal or abdominal hysterectomy for nonmalignant disease. Trovafloxacin Surgical Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900224-4

Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin. Trovafloxacin Surgical Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900224-4

Treatment of acute gynecologic infections with trovafloxacin. Trovafloxacin Surgical Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900224-4

Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2898%2900224-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9610(98)00224-4

1 reference

4 August 2017

1 reference